UK Innovation & Science Seed Fund Invests in Seven Companies

UK Innovation & Science Seed Fund (UKI2S) , formerly known as Rainbow Seed Fund, a Harwell, Oxford-based early-stage venture capital fund focused on promising technologies based on the UK’s publicly-funded research, has invested in seven companies.

The investment was made via the Government’s Innovate UK (IUK) £8.5m investment accelerator, which combines equity and grant funding to back high-potential therapeutic, diagnostic and device companies.

The new joint IUK and UKI2S investments include:

Camstech, which develops novel sensing technology used for point-of-care diagnostics.
SFH Oxford, which has been developing Graducheck, a sensor-based technology for improving the application of compression bandages for treatment of venous leg ulcers – a chronic wound that is a considerable burden; both for the patients and national healthcare systems.
C-Major Medical, an innovative medtech company based at the Daresbury Campus focused on developing a novel syringe platform technology – CHoRD (Controlled Helical Retraction Device). The platform will be used to produce a range of devices to reduce the risk of needle stick injuries in clinical settings and promote safety of health staff.

MyoDOPA, which addresses limitations associated with current treatments of Parkinson’s disease and develops a novel therapeutic profile providing efficient treatment of PD without the need for a PEG tube, pump or neurosurgery.
Linear Diagnostics, which started as a spin out from the University of Birmingham, is advancing a molecular diagnostics platform that rapidly detects key genetic sequences.
Cagen, which has developed protein nanocages that allow the delivery of poorly soluble and poorly bioavailable molecules into cells.
Nemesis Bioscience, which is developing ‘Symbiotics’​-novel DNA therapeutics that remove antibiotic resistance.



Join the discussion